Free Trial

Barinthus Biotherapeutics (BRNS) Stock Price, News & Analysis

-0.05 (-2.21%)
(As of 05/24/2024 03:27 PM ET)
Today's Range
50-Day Range
52-Week Range
19,300 shs
Average Volume
18,328 shs
Market Capitalization
$86.26 million
P/E Ratio
Dividend Yield
Price Target

Barinthus Biotherapeutics MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
262.0% Upside
$8.00 Price Target
Short Interest
0.05% of Float Sold Short
Dividend Strength
News Sentiment
0.98mentions of Barinthus Biotherapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($2.30) to ($2.53) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.98 out of 5 stars

Medical Sector

608th out of 921 stocks

Pharmaceutical Preparations Industry

277th out of 431 stocks

BRNS stock logo

About Barinthus Biotherapeutics Stock (NASDAQ:BRNS)

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

BRNS Stock Price History

BRNS Stock News Headlines

BRNS Barinthus Biotherapeutics plc
See More Headlines
Receive BRNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Barinthus Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Previous Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$4.85 per share


Free Float
Market Cap
$86.26 million
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. William J. Enright MBA (Age 62)
    CEO & Director
    Comp: $969.44k
  • Dr. Nadege Pelletier Ph.D. (Age 45)
    Chief Scientific Officer
    Comp: $593.48k
  • Mr. Graham Griffiths (Age 44)
    Chief Business Officer
    Comp: $522.23k
  • Ms. Sarah Gilbert
  • Mr. Adrian Hill Ph.D.
    Co-Founder & Scientific Advisor
  • Ms. Gemma Brown (Age 33)
    CFO & Company Secretary
  • Ms. Elizabeth Eagling-Vose M.B.A.
    Head of Clinical Operations
  • Bernie McDonald
    Head of IP
  • Geoffrey Lynn
    Senior Vice President of Synthetic Immunotherapies

BRNS Stock Analysis - Frequently Asked Questions

Should I buy or sell Barinthus Biotherapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Barinthus Biotherapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BRNS shares.
View BRNS analyst ratings
or view top-rated stocks.

What is Barinthus Biotherapeutics' stock price target for 2024?

2 Wall Street research analysts have issued 12-month target prices for Barinthus Biotherapeutics' shares. Their BRNS share price targets range from $8.00 to $8.00. On average, they expect the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 262.0% from the stock's current price.
View analysts price targets for BRNS
or view top-rated stocks among Wall Street analysts.

How have BRNS shares performed in 2024?

Barinthus Biotherapeutics' stock was trading at $3.69 at the beginning of the year. Since then, BRNS stock has decreased by 40.1% and is now trading at $2.21.
View the best growth stocks for 2024 here

When is Barinthus Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our BRNS earnings forecast

How were Barinthus Biotherapeutics' earnings last quarter?

Barinthus Biotherapeutics plc (NASDAQ:BRNS) posted its earnings results on Wednesday, March, 20th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.10.

Who are Barinthus Biotherapeutics' major shareholders?

Barinthus Biotherapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include DC Funds LP (1.65%) and BlueCrest Capital Management Ltd (1.39%).

How do I buy shares of Barinthus Biotherapeutics?

Shares of BRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BRNS) was last updated on 5/27/2024 by Staff

From Our Partners